# Tesamorelin References: The Cited Studies Behind the Record

> Tesamorelin references: the full citation register behind this digest, with PubMed and DOI links to the trials, the FDA label, the LiverTox monograph, and the 2026 meta-analysis.

Every figure on this site traces to one of these sources — the pivotal trials, the FDA prescribing label, the LiverTox monograph, the pharmacokinetic and safety studies, and the 2026 meta-analysis.

## How this register is used

Each numbered entry below corresponds to the inline [N] markers across the research, side-effects, vs-sermorelin, dosage, and FAQ pages. Where a finding states a number — a percentage, a dose, a half-life, a p-value — that number is carried back to one of these sources. Regulatory and safety framing draws on the FDA prescribing label [1] and the NIH LiverTox monograph [4]; the efficacy record rests on the pivotal and long-term HIV trials [5][6] and the 2026 meta-analysis [15]. The [full reference list](/references) is the record's evidentiary spine — the field that makes every other field verifiable.

## References

[1] Theratechnologies Inc. Tesamorelin for injection — Full Prescribing Information (FDA-approved labeling, NDA 022505). U.S. FDA Prescribing Information. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
[2] Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. https://pubmed.ncbi.nlm.nih.gov/28617838/
[3] Teng S, et al. Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2013;2:237-45. https://pubmed.ncbi.nlm.nih.gov/27121785/
[4] National Institute of Diabetes and Digestive and Kidney Diseases. Tesamorelin — LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf (NIH). 2018. https://www.ncbi.nlm.nih.gov/books/NBK548730/
[5] Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370. https://pubmed.ncbi.nlm.nih.gov/18057338/
[6] Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. https://pubmed.ncbi.nlm.nih.gov/18690162/
[7] Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. https://pubmed.ncbi.nlm.nih.gov/25038357/
[8] Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. Journal of Clinical Endocrinology and Metabolism. 2011;96(1):150-158. https://pubmed.ncbi.nlm.nih.gov/20943777/
[9] Falutz J, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19:1279-87. https://pubmed.ncbi.nlm.nih.gov/16052083/
[10] Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic & Clinical Pharmacology & Toxicology. 2007;100:49-58. https://pubmed.ncbi.nlm.nih.gov/17214611/
[11] Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, Aberg JA. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of Clinical and Translational Science. 2023;7(1):e40. https://pubmed.ncbi.nlm.nih.gov/36845310/
[12] Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Annals of Pharmacotherapy. 2012;46(2):240-247. https://pubmed.ncbi.nlm.nih.gov/22298602/
[13] Wang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opinion on Investigational Drugs. 2009;18:303-10. https://pubmed.ncbi.nlm.nih.gov/19243281/
[14] Veldhuis JD, Erickson D, et al. Endogenous Estrogen Regulates Somatostatin-Induced Rebound GH Secretion in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism. 2016;101:4298-4304. https://pubmed.ncbi.nlm.nih.gov/27459535/
[15] Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity Research & Clinical Practice. 2026. https://pubmed.ncbi.nlm.nih.gov/41545261/

---

The tesamorelin literature read as a validated record — every figure typed to its field and carried back to its study, the FDA scope (HIV-associated lipodystrophy only), the labeled contraindications, and the off-label edge surfaced as the record's leading status; a digest that flags before it reports, never a clinic, a vendor, or a prescription.